Press release
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities
Vitual fireside chat with members of Compugen's management team will take place on June 8 at 12:00 PM ET HOLON, Israel, June 1, 2021 /PRNewswire/ -- Compugen
About this update from Compugen Ltd.
[{"type":"text","content":"Vitual fireside chat with members of Compugen's management team will take place on June 8 at 12:00 PM ET\n\n\nHOLON, Israel, June 1, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that members of its senior management team will participate in a virtual event to discuss data from its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, as a monotherapy and in combination with nivolumab. The data will be presented in an oral presenation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, on June 7, 2021. \nThe vitual fireside chat, hosted by Asthika Goonewardene, Truist Securities Biotech Analyst, will take place on June 8, 2021 at 12:00 PM ET. \nParticipating on behalf of Compugen are Anat Cohen-Dayag, PhD, President and CEO; Ari Krashin, Chief Financial and Operating Officer; Henry Adewoye, PhD, Senior Vice President and Chief Medical Officer and Eran Ophir, PhD, Vice President, Research and Drug Discovery.\nThe event will also be available via live webcast through Compugen's website, located at the following link.\nAbout Compugen\nCompugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. Compugen's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com. \nForward-Looking Statement \nThis press release contains \"forward-looking statements\" within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securitie...